Chart Analysis
PKY Daily Timeframe Chart as of 29 April 2026
Pathkey.AI (ASX: PKY) — Acquires AI-Powered Semiconductor Chip Design Platform Chipforge via All-Scrip Deal
On 29 April 2026, Pathkey.AI Ltd (ASX: PKY) announced it has entered into a binding share purchase agreement to acquire 100% of Singapore-based Chipforge Pte Ltd, an AI-driven semiconductor hardware design and verification technology company. The agreement grants PKY an irrevocable option to acquire Chipforge, exercisable within two months (extendable by a further two months for A$200,000). Chipforge is developing an agentic AI platform that translates high-level design intent into verified, synthesisable hardware code — a process that conventionally takes 12–24 months and multi-million-dollar expenditure using specialised hardware engineers. The platform's core technology is licensed under an exclusive worldwide licence from Nanyang Technological University (NTU) in Singapore via Ntuitive Pte Ltd. Consideration comprises 560 million PKY shares and 150 million performance rights, with no capital raising contemplated. The company describes the acquisition as complementary to its existing TrialKey clinical trial AI platform, with both built on agent-based AI architectures combining large-language-model functionality with neuro-symbolic reasoning.
Key Details at a Glance
| Detail | Value |
|---|---|
| Target | Chipforge Pte Ltd (Singapore, Company Number 202556247M) |
| Acquisition Structure | Binding SPA with irrevocable option; all-scrip consideration |
| Consideration Shares | 560,000,000 PKY shares at deemed issue price of A$0.022 |
| Performance Rights | 150,000,000 (two classes, 18-month expiry) |
| Chipforge Debt Repayment | Up to A$500,000 (convertible note principal) |
| Capital Raising | None contemplated |
| PKY Cash (31 March 2026) | ~A$3,260,000 |
| Expected R&D Rebates (12 months) | ~A$840,000 |
| Technology Licence | Exclusive worldwide licence from NTU via Ntuitive Pte Ltd |
| Shareholder Approval Required | Yes — Listing Rule 7.1 (General Meeting ~15 June 2026) |
| Expected Completion | Prior to end of FY2026 (~18 June 2026) |
| Ntuitive Consent | Required as condition precedent (change of control) |
What is Chipforge — AI-Powered Semiconductor Design Platform
Chipforge is developing an AI platform for semiconductor chip design and verification. The platform is designed to allow engineers to describe what they want a chip to do — through specifications, diagrams, or functional requirements — and the system generates the underlying hardware description language (HDL) code, builds verification tests, and progresses the design through synthesis and implementation on FPGA hardware. The platform's roadmap extends toward full Application-Specific Integrated Circuit (ASIC) development.
The company targets two stages of the chip design process that represent significant bottlenecks: translating design concepts into precise hardware code, and verifying that the design works as intended before it is committed to silicon. Verification alone routinely consumes more than half of a chip project's total budget and timeline, according to the announcement.
Chipforge's target markets include defence, aerospace, critical infrastructure, universities and research institutions, and companies developing custom chips for AI, edge computing, and embedded systems — sectors where demand for sovereign, locally controlled chip design capability is described as growing.
Ntuitive Licence — Nanyang Technological University IP
Chipforge's core technology is licensed under an exclusive, worldwide licence agreement (with right to sub-licence) from Ntuitive Pte Ltd, Nanyang Technological University's technology transfer company. The licence includes proprietary documentation and know-how.
The licence contains minimum development and commercialisation milestones that Chipforge must meet to retain exclusivity:
- Raise at least S$1,000,000 by 2 February 2027
- Achieve first commercial sale of a licensed product by 2 February 2028
- Generate cumulative net revenue of S$1,000,000 by 2 February 2031
Annual licensing fees commence at S$20,000 per annum and increase progressively to S$50,000 per annum over a 16-year period. Ntuitive's consent to the change of control of Chipforge is a condition precedent to the acquisition.
Acquisition Consideration and Dilution
The total consideration comprises 560 million fully paid ordinary shares at a deemed issue price of A$0.022 per share, plus 150 million performance rights convertible to shares on a one-for-one basis within 18 months, subject to the following milestones:
| Class | Number | Milestone |
|---|---|---|
| A | 75,000,000 | Demonstration of a minimum viable product within 9 months, verified by an independent expert from a recognised Australian or Singaporean university |
| B | 75,000,000 | Entry into at least one binding commercial agreement leveraging Chipforge IP with a credible customer that will deliver revenue within 12 months |
PKY will also repay up to A$500,000 of Chipforge convertible note debt on completion.
Capital structure impact:
| Item | Current | Post-Acquisition |
|---|---|---|
| Shares on issue | 607,077,750 | 1,167,077,750 |
| Options | 300,251,467 | 300,251,467 |
| Performance Rights | Nil | 150,000,000 |
The 560 million consideration shares represent a ~92% increase in the current share count. If all performance rights vest, the total dilution rises to ~117%.
The Chipforge board has the right to nominate one non-executive director to the PKY board within 12 months of completion.
Use of Funds and Cash Position
PKY held approximately A$3,260,000 in cash as at 31 March 2026 and expects approximately A$840,000 in R&D rebates and other income over the next 12 months.
| Use of Funds (Next 12 Months) | Amount |
|---|---|
| TrialKey platform development | A$1,550,000 |
| Chipforge platform development | A$1,500,000 |
| Working capital and corporate administration | A$700,000 |
| Estimated transaction costs | A$350,000 |
| Total | A$4,100,000 |
The company states it does not currently anticipate undertaking a capital raising in connection with the acquisition and considers itself funded for the next 12 months based on existing reserves and expected receipts.
Strategic Rationale — TrialKey and Chipforge Synergies
PKY's existing platform, TrialKey, is a proprietary AI engine applied to clinical trial design and optimisation. The company describes both TrialKey and Chipforge as built on the same agent-based AI architecture combining LLM functionality with neuro-symbolic reasoning to solve complex design optimisation problems. In both platforms, AI agents generate candidate solutions, evaluate them against defined objectives, and iteratively refine them through a structured reflection loop.
The company states that know-how developed for TrialKey can be directly applied to Chipforge development and vice versa. The acquisition follows a strategic review completed during H1 FY2026 that identified complementary AI technology acquisitions as a core growth strategy.
Market Context
PKY closed at $0.052 on the announcement day, up +26.8% from a previous close of $0.041, with an intraday high of $0.071. The 52-week range spans $0.013 to $0.071. The consideration shares are issued at a deemed price of A$0.022, which is significantly below the current trading price.
Risks & Considerations
Pre-revenue technology: Chipforge is a development-stage company with no commercial revenue, no customers, and no completed product. The platform is described in terms of what it is "developing" and "designed to" do — no working product has been demonstrated at the time of the announcement.
Significant dilution: The 560 million consideration shares represent a ~92% increase in current shares on issue. If all 150 million performance rights vest, total dilution reaches ~117%. The deemed issue price of A$0.022 per share is at a substantial discount to the current market price.
Ntuitive licence milestones: Chipforge must meet minimum development and commercialisation milestones to retain its exclusive licence from NTU, including raising S$1 million by February 2027, achieving a first commercial sale by February 2028, and generating S$1 million cumulative revenue by February 2031. Failure to meet these milestones could result in loss of exclusivity.
Ntuitive consent required: The acquisition is conditional on Ntuitive consenting to the change of control of Chipforge. There is no certainty this consent will be granted.
No capital raising — but limited runway: While no capital raising is contemplated, the company's total funding plan of A$4.1 million over 12 months relies on existing cash (A$3.26M) plus expected R&D rebates and other income (A$840K). If development costs exceed estimates or rebates are delayed, additional funding may be required.
Unrelated business combination: PKY's existing business is an AI clinical trial platform. The acquisition of a semiconductor chip design platform represents a significant strategic pivot into an unrelated industry. The claimed synergies (shared AI architecture) are conceptual and have not been commercially validated.
Shareholder approval required: The acquisition requires shareholder approval under Listing Rule 7.1, with a general meeting expected on 15 June 2026. There is no certainty approval will be obtained.
Competitive landscape: The AI-assisted chip design space includes established EDA (Electronic Design Automation) companies such as Synopsys and Cadence, as well as internal AI design tools being developed by major semiconductor companies. Chipforge's ability to compete with these incumbents is unproven.
Singapore-based with nominee structure: Chipforge is a Singapore company, and post-completion certain shares will be held via a nominee arrangement under a declaration of trust. This introduces cross-jurisdictional complexity.
Key Dates & Timeline
| Date | Event |
|---|---|
| 29 April 2026 | Binding SPA announced; share price moved +26.8% |
| ~14 May 2026 | Dispatch of Notice of General Meeting |
| ~15 June 2026 | General Meeting — shareholder vote on acquisition |
| ~18 June 2026 | Expected completion of acquisition |
| Within 2 months of SPA (extendable +2 months) | Option exercise deadline |
| 9 months post-issue | Class A Performance Right milestone (MVP demonstration) |
| 12 months post-issue | Class B Performance Right milestone (binding commercial agreement) |
| 2 February 2027 | Ntuitive licence milestone — raise S$1,000,000 |
| 2 February 2028 | Ntuitive licence milestone — first commercial sale |
| 2 February 2031 | Ntuitive licence milestone — S$1,000,000 cumulative revenue |
Price Data
- Previous Close: $0.041
- Close Price (29 April 2026): $0.052
- Change (29 April 2026): +26.8%
- 52-Week Range: $0.013 – $0.071
Notable Price Levels
- $0.071 — 52-week high, set intraday on 29 April 2026
- $0.052 — announcement-day close
- $0.041 — pre-announcement close
- $0.029 — prior trading range
- $0.026 — earlier consolidation zone
- $0.022 — deemed issue price for Chipforge consideration shares
Key Takeaways
- PKY moved +26.8% on 29 April 2026 following a price-sensitive ASX disclosure, with an intraday high of $0.071 (+73%).
- The announcement — PKY to Acquire AI Semiconductor Design Verification Platform — was the primary catalyst for the price movement.
- Pathkey.AI is acquiring 100% of Singapore-based Chipforge Pte Ltd, an AI-driven semiconductor chip design and verification platform, for 560 million shares and 150 million performance rights — a ~92% increase in shares on issue before performance right conversion.
- Chipforge's core technology is licensed exclusively from Nanyang Technological University (NTU) via Ntuitive, subject to minimum development and revenue milestones through to 2031.
- No capital raising is contemplated. PKY held A$3.26 million in cash at 31 March 2026 and plans to allocate A$1.5 million to Chipforge development over the next 12 months.
- Chipforge is pre-revenue with no demonstrated product, no customers, and no commercial agreements. The acquisition requires shareholder approval at a general meeting expected 15 June 2026.
Summary
Pathkey.AI announced a binding agreement to acquire 100% of Singapore-based Chipforge Pte Ltd, an AI-driven semiconductor hardware design and verification platform, for 560 million PKY shares (at A$0.022 deemed issue price) and 150 million performance rights — representing a ~92% increase in shares on issue. The announcement coincided with a +26.8% move to $0.052, with an intraday high of $0.071. Chipforge is developing an agentic AI platform that translates high-level chip design intent into verified hardware code, with core technology licensed exclusively from Nanyang Technological University. The platform is pre-revenue with no demonstrated product or customers. The acquisition requires shareholder approval (general meeting ~15 June 2026), Ntuitive consent to change of control, and completion of confirmatory due diligence. No capital raising is contemplated, with PKY holding A$3.26 million in cash and planning A$4.1 million in expenditure over the next 12 months across both TrialKey and Chipforge platforms.
This article is for informational purposes only and does not constitute financial advice. Market Flow does not recommend buying or selling any securities. Past performance is not indicative of future results. Readers should conduct their own independent research and consult a licensed financial adviser before making any investment decisions. This content is published in accordance with ASX Market Rules and is not a financial product recommendation.